Zobrazeno 1 - 9
of 9
pro vyhledávání: '"E. V. Karyagina"'
Autor:
S. S. Bessmeltsev, E. V. Karyagina, L. V Stelmashenko, N. V. Stepanova, E. R. Machulaiten, G. N. Salogub, I. A. Skorokhod, N. V. Medvedeva, E. I. Podoltseva, L. M. Matyukhina, A. S. Nizamutdinova, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 52-62 (2022)
The characteristics of peripheral neuropathy (PN), its incidence and a possibility of relieving in multiple myeloma (MM) patients receiving bortezomib are presented. A hundred and twenty-four patients with recurrent/refractory MM and 14 primary patie
Externí odkaz:
https://doaj.org/article/d13b8f52d7bd41c4a2309ca155e24f5c
Publikováno v:
Онкогематология, Vol 0, Iss 3, Pp 15-22 (2022)
Efficiency of alemtuzumab (Campath) in 8 patients with chronic lymphocytic leukemia (CLL) was reported. Patients treated with alemtuzumab or alemtuzumab in combination with fludarabine (FluCam). Therapy response, overall survival and incidence of sid
Externí odkaz:
https://doaj.org/article/2794f39681354c5583e3cb76794443c7
Autor:
V. G. Potapenko, E. V. Baumert, A. A. Bobrova, R. V. Vashchenkov, N. V. Dorofeeva, K. D. Kaplanov, E. V. Karyagina, A. N. Levanov, A. S. Luchinin, S. I. Moiseev, A. V. Novitskii, A. S. Nizamutdinova, О. V. Pirogova, S. A. Povzun, М. V. Platonov, V. V. Porunova, D. А. Ptashnikov, V. V. Ryabchikova, S. Ya. Simeniv, I. А. Skorokhod, Е. А. Ukrainchenko, D. А. Chaginskaya, T. V. Shelekhova, M. N. Shirokova, A. A. Shutylev, N. V. Medvedeva
Publikováno v:
Онкогематология, Vol 17, Iss 3, Pp 48-61 (2022)
Background. The treatment options for patients with multiple myeloma who refractory to previous bortezomib and lenalidomide therapy are limited. Pomalidomide is ап immunomodulatory agent that was registered for the treatment of patients with double
Externí odkaz:
https://doaj.org/article/df93b644f61c43f1a2b7b163a8dd215b
Autor:
V. G. Potapenko, A. V. Klimovich, M. Yu. Pervakova, S. V. Lapin, O. V. Goloshchapov, A. K. Titov, E. A. Surkova, E. S. Pavluchenko, N. A. Potikhonova, N. V. Vinogradova, E. V. Doguzhieva, G. V. Kachenya, D. D. Avdoshina, I. P. Fedunyak, V. V. Ryabchikova, T. G. Kulibaba, A. V. Rysev, E. V. Karyagina, N. V. Мedvedeva
Publikováno v:
Онкогематология, Vol 15, Iss 4, Pp 52-64 (2020)
Background. Secondary hemophagocytic lymphohystiocytosis (sHLH) is a hyperinflammatory reaction provoked by some trigger (cancer, autoimmune or infection). The majority of affected patients are at high risk of fatal multiple organ failure without get
Externí odkaz:
https://doaj.org/article/c9c0d6634f6a43569a5d3b1cdcf15153
Publikováno v:
Медицинская иммунология, Vol 21, Iss 4, Pp 703-714 (2019)
Multiple myeloma is the most common form of paraproteinemic hemoblastosis, which is characterized by variability of clinical manifestations, forms, and variants. Limited efficiency of antitumor immune protection in the patient plays an important role
Externí odkaz:
https://doaj.org/article/56d50776590c4e799c6adb58732f1d12
Autor:
I. A. Samorodova, S. N. Bondarenko, V. N. Ovechkina, A. V. Klimovich, E. I. Podolceva, N. V. Medvedeva, A. S. Nizamutdinova, E. V. Karyagina, B. I. Smirnov, I. S. Moiseev, L. S. Zubarovskaya, B. V. Afanasyev
Publikováno v:
Онкогематология, Vol 13, Iss 1, Pp 8-20 (2018)
Introduction. The question of the most adequate treatment strategy of AML in cases when it is impossible to perform allogeneic HSCT because of any reason still remains open.The aim of this study was to assess the long-term survival of patients with A
Externí odkaz:
https://doaj.org/article/e9677f13eb234f46bc06ba86a1ead79c
Autor:
S. V. Voloshin, S. S. Bessmeltsev, T. P. Zagoskina, N. V. Medvedeva, K. D. Kaplanov, E. V. Karyagina, A. D. Garifullin, A. Yu. Kuvshinov, L. V. Stelmashenko, K. M. Abdulkadyrov
Publikováno v:
Онкогематология, Vol 10, Iss 3, Pp 10-17 (2015)
Relapsed and refractory (R/R) multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short. In patients with R/R MM after therapy
Externí odkaz:
https://doaj.org/article/3a9bc84bcc124ee88a5b7e2d94b39c1b
Autor:
I. A. Lisukov, A. A. Maschan, A. V. Shamardina, T. V. Chagorova, I. L. Davydkin, T. M. Sycheva, T. P. Zagoskina, E. V. Karyagina, G. N. Salogub, M. T. Savinova, T. V. Shelekhova, L. G. Kovaleva, T. V. Shneyder, A. N. Unzhekova, E. E. Kuznetsova, Yu. V. Shatokhin, M. O. Ivanova, E. Yu. Vinogradova, E. M. Volodicheva, I. V. Markova, O. V. Kanyukova, K. M. Abdulkadyrov, Yu. A. Sedlova, S. M. Osyunikhina, K. D. Kaplanov, N. V. Tsvetaeva, A. R. Akhmadeev, O. S. Uspenskaya, A. D. Kulagin, N. V. Medvedeva, A. G. Rumyantsev, B. V. Afanasiev
Publikováno v:
Онкогематология, Vol 8, Iss 2, Pp 61-69 (2014)
Primary immune thrombocytopenia (ITP) is a rare (orphan) blood disease. Most frequent manifestations of ITP are purpura, petechiae and bleedings with many patients have either no symptoms or minimal bleedings manifestation. The management of ITP vari
Externí odkaz:
https://doaj.org/article/8486090d30434d0b8dce282be0f263c6
Autor:
A. M Radzhabova, S. V Voloshin, I. S Martynkevich, A. A Kuzyaeva, VA. Shuvaev, E. V Motyko, A. Y Kuvshinov, M. S Fominykh, A. V Schmidt, L. B Polushkina, M. P Bakay, S. A Tiranova, M. N Zenina, N. A Potihonova, SA. Kudryashova, V. A Balashova, J. V Chubukina, O. S Uspenskaya, E. V Karyagina, A. N Bogdanov, A. V Chechetkin
Publikováno v:
Genes & Cells. 14:55-61
Detection of FLT3 gene mutations in acute myeloid leukemia is now recognized as an unfavorable factor that affects the disease course, emerging the risk of relapses and overall survival shortening and disease-free survival of patients. The aim of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4af4b36307e43e7d49984a402281ca53
https://doi.org/10.23868/201903007
https://doi.org/10.23868/201903007